GlassScriptPhysician profile
Timothy Andrew Mccarthy
NPI 1881963403
$4,955.41
in general payments reported to CMS, 2019-2025
44 companies · $745 in 2025
The $745 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $178 · 2021: $52.45 · 2022: $1,578 · 2023: $697 · 2024: $1,251 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,500.00 | 2022 | |
| Amgen INC. | $338.27 | 2019-2023 | Kyprolis, Blincyto |
| Janssen Biotech, INC. | $313.28 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $294.84 | 2019-2025 | Tagrisso, Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $292.88 | 2022-2025 | |
| Daiichi Sankyo INC. | $237.64 | 2019-2025 | Enhertu, Injectafer |
| Abbvie INC. | $156.52 | 2024-2025 | |
| Incyte Corporation | $152.40 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Smith+Nephew, INC. | $138.45 | 2024 | |
| Pharmacosmos Therapeutics INC. | $110.02 | 2025 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $107.70 | 2022-2024 | Onivyde, Somatuline Depot, Tazverik |
| Merck Sharp & Dohme LLC | $104.57 | 2019-2023 | Keytruda, Lynparza |
| Pfizer INC. | $99.70 | 2019-2025 | |
| Bioprotect Medical, INC. | $93.70 | 2024 | Bioprotect Balloon Implant System |
| Gilead Sciences, INC. | $87.78 | 2021-2024 |
Show all 41 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.